Eugenio Catone
Eugenio Catone @CatoneEugenio

Performance
All

-0.88%2026
2026
19.34%2025
2025
18.98%2024
2024
64.17%2023
2023
-6.87%2022
2022
64.2%0%-64.2%
Eugenio Catone
While 90-day delinquencies on mortgages are at fairly low levels—and thus far from 2008 crisis, take a look at other types of loans. It’s not often discussed, but delinquencies on auto loans and credit cards have reached the peak levels seen during that crisis. At the same time, student loan delinquencies... Show More
Eugenio Catone
Semiconductor companies are losing ground today, and in a way, this comes as no surprise. The SOXX (semiconductor ETF) / Nasdaq ratio is currently in line with levels seen during the dot-com bubble. In other words, there is a lot of euphoria, but it doesn't take much to trigger significant downward... Show More
Eugenio Catone
In April 2026, the S&P 500 index posted one of its best performances ever, even though the war in the Middle East is far from over. However, one interesting point to note is how the new all-time highs were reached. Typically, a healthy bull market involves a large number of companies performing... Show More
Eugenio Catone
April was a fairly positive month, and the year-to-date return is back above zero. As is often the case, a significant decline is followed by a rebound. The market seems to have completely ignored the fact that the Strait of Hormuz is still closed (we’re on day 62), which pleased me but didn’t eliminate... Show More
Eugenio Catone
March ended with a decline of slightly more than 5%, in line with the drop in major U.S. stock indices. Clearly, the war in the Middle East is having a negative impact; in fact, it is driving energy costs sky-high at the expense of companies/households. Furthermore, since rising oil prices are historically... Show More
Eugenio Catone
February ended with a decline of 2.35%, which was not an exciting result but in line with a general decline (S&P 500 -0.89% and Nasdaq Composite -3.38%). The portfolio's performance was certainly affected by Novo Nordisk's poor quarterly results, a position that I sold in its entirety. In... Show More
Eugenio Catone
After a strong rally in January, February began with some headwinds. Both Novo Nordisk and Evolution released their Q4 2025 results, and they were disappointing to say the least. The former released guidance that was completely at odds with my expectations (the Wegovy pill is having a backfire effect),... Show More
Eugenio Catone
Nei mesi precedenti avevo menzionato la mia volontà di aumentare la liquidità ed in effetti è stato così. Ad ogni modo, il fatto che io stia predilegendo un approccio più "risk off" non significa che eviterò qualsiasi investimento, semplicemente i miei criteri di investimento saranno più stringenti.... Show More Translate
Eugenio Catone
The year is now drawing to a close and it is time to take stock. Performance for 2025 will probably be around 19-20%, slightly up compared to 2024. 2025 has been a very bullish year and I am satisfied with the results considering that the risk score has often been quite low (3-4). 2025 will be the... Show More
Eugenio Catone
The FDA approved the Wegovy pill, the first oral GLP-1 for obesity in the US. After months of doubts, this approval feels like a true turning point. The pill delivered 16.6% average weight loss in 64 weeks, with durable results and cardiovascular benefits, outperforming Eli Lilly’s upcoming oral competitor.... Show More

About Eugenio Catone
Italy
Strategy: Value

Long-term view; I only invest in exceptional businesses. Minimum copy amount: $200
Show Full Bio
53 Copiers
2.5K Followers